MedTrace Logo

Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)

NCT07170748 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2950

Last updated 2026-02-02

No results posted yet for this study

Summary

Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.

Conditions

  • Multiplex Testing of HIV, HBV, HCV and Syphilis
  • HIV
  • HBV
  • HCV
  • Syphilis
  • Point of Care Testing

Sponsors & Collaborators

  • Institut Pasteur

    collaborator INDUSTRY

  • Kenya Medical Research Institute

    collaborator OTHER

  • Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire

    collaborator OTHER

  • MagIA Diagnostics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-29
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Côte d’Ivoire
  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07170748 on ClinicalTrials.gov